Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients

Blood

Volumn 90, Issue 6, 1997, Pages 2196-2206

  Lieberman, Judy ^a   Skolnik, Paul R ^b   Parkerson III, G Robert ^b   Fabry, Jessica A ^b   Landry, Bernard ^b   Bethel, James ^b   Kagan, Jonathan ^b  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 120; NEF PROTEIN;

ADULT; ARTICLE; BLOOD AUTOTRANSFUSION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MARKER; HOMOSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SAFETY; T LYMPHOCYTE SUBPOPULATION; VIREMIA;

EID: 0030854210     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2196     Document Type: Article

References (48)

1. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS, Schooley RT: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345, 1987
2. Plata F, Autran B, Martins LP, Wain-Hobson S, Raphael M, Mayaud C, Denis M, Guillon JM, Debre P: AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 328:348, 1987
3. Walker CM, Moody DJ, Stites DP, Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563, 1986
4. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811, 1995
5. Baier M, Werner A, Bannert N, Metzner K, Kurth R: HIV suppression by interleukin-16. Nature 378:563, 1995
6. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650, 1994
7. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103, 1994
8. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, Vilmer E, Michel F, Mayaud C, Autran B, Plata F: Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 142:452, 1989
9. Mawle AC, Ridgeway MR, Kieny M-P, Lifson AR: CTL response to p24 (Gag) in long-term asymptomatic seropositive individuals infected with HIV-1. VI International Conference on AIDS. University of California, San Francisco, CA, 1990 (abstr SA254)
10. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, Pialoux G, Feuillie V, Mollereau M, Chamaret S, Takaia F, Montagnier L: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 11:903, 1995
11. Kourtis AP, Ibegbu C, Nahmias AJ, Lee FK, Clark WS, Sawyer MK, Nesheim S: Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 335:1431, 1996
12. Autran B, Mayaud CM, Raphael M, Plata F, Denis M, Bourguin A, Guillon JM, Debre P, Akoun G: Evidence for a cytotoxic T-lymphocyte alveolitis in human immunodeficiency virus-infected patients. AIDS 2:179, 1988
13. Sethi KK, Naher H, Stroehmann I: Phenotypic heterogeneity of cerebrospinal fluid-derived HIV-specific and HLA-restricted cytotoxic T-cell clones. Nature 335:178, 1988
14. Zinkernagel RM: Are HIV-specific CTL responses salutary or pathogenic? Curr Opin Immunol 7:462, 1995
15. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey V, Pantaleo G, Demarest JF, Carter C, Wannebo C, Yanelli JR, Rosenberg SA, Lane HC: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1:330, 1995
16. Dailey MO, Pillemer E, Weissman IL: Protection against syngeneic lymphoma by a long-lived cytotoxic T cell clone. Proc Natl Acad Sci USA 79:5384, 1982
17. Engers HD, La Haye T, Sorenson GD, Glasebrook AL, Horvath C, Brunner TK: Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMuLV-specific T cell clones. J Immunol 133:1664, 1984
18. Plata F, Langlade-Demoyen P, Abastado JP, Berbar T, Kourilsky P: Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo. Cell 48:231, 1987
19. Yap KL, Ada GL, McKenzie IFC: Transfer of specific cytotoxic T lymphocytes protect mice inoculated with influenza virus. Nature 273:238, 1978
20. Klavinskis LS, Whitton JL, Oldstone MB: Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol 63:4311, 1989
21. van Kuyk R, Torbett BE, Gulizia RJ, Leath S, Mosier DE, Koenig S: Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J Immunol 153:4826, 1994
22. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ: Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 Scid/Scid mice. J Exp Med 183:1215, 1996
23. Buchsbaum RJ, Fabry JA, Lieberman J: EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunol Lett 52:145, 1996
24. Rosenberg SA, Lotzke MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889, 1987
25. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalin SL, Toy ST, Simon P, Lotze MT, Yang JC, Siepp CA, Simpson C, Carter C, Bock S, Schwartzentrober D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report. N Engl J Med 319:1676, 1988
26. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995
27. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238, 1992
28. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
29. + cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus. Blood 81:2085, 1993
30. Torpey DD, Huang XL, Armstrong J, Ho M, Whiteside T, McMahon D, Pazin G, Heberman R, Gupta P, Tripoli C, Moody D, Okarma T, Elder E, Rinaldo C Jr: Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: Lymphocyte subsets and cytotoxic activity. Clin Immunol Immunopathol 68:263, 1993
31. Lieberman J, Fabry JA, Shankar P, Beckett L, Skolnik PR: Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retroviruses 11:257, 1995
32. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216, 1996
33. Moss PA, Rowland-Jones SL, Frodsham PM, McAdam S, Giangrande P, McMichael AJ, Bell JI: Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 92:5773, 1995
34. Lieberman J, Fabry JA, Kuo MC, Earl P, Moss B, Skolnik PR: Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J Immunol 148:2738, 1992
35. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 41:1, 1993
36. Castro BA, Weiss CD, Wiviott LD, Levy JA: Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol 26:2371, 1988
37. AIDS Clinical Trials Group: Quantitative PBMC Microculture Assay, in Hollinger FB (ed): Virology Manual for HIV Laboratories. Bethesda, MD, Division of AIDS, NIAID, 1993, p MIC1
38. Bollinger RC Jr, Kline RL, Francis HL, Moss MW, Bartlett JG, Quinn TC: Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons. J Infect Dis 165:913, 1992
39. Eyster ME, Fried MW, DiBisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Blood 84:1020, 1994
40. Ratner L, Haseltine W, Patarca, R, Livak, KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, et al: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277, 1985
41. Lieberman J, Fabry JA, Fong DM, Parkerson GR Jr: Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocyte response to HIV-1 in an infected individual. AIDS Res Hum Retroviruses 13:383, 1996
42. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, McMichael AJ: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453, 1991
43. Cheynier R, Langlade-Demoyen P, Marescot MR, Blanche S, Blondin G, Wain-Hobson S, Griscelli C, Vilmer E, Plata F: Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol 22:2211, 1992
44. Clerici M, Giorgio JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho H-N, Nishanian PG, Berzofsky JA, Shearer GM: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 165:1012, 1992
45. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, Oksenhendler E: Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest 93:1293, 1994
46. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, Whittle H: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1:59, 1995
47. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, Gupta P: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 69:5838, 1995
48. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, Walker BD: Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 12:585, 1996